Patents by Inventor Dean Franklin Rigel

Dean Franklin Rigel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors
    Patent number: 10112963
    Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides pharmaceutical composition of the compounds of the invention and a combination of pharmacologically active agents and a compound of the invention.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: October 30, 2018
    Assignee: Novartis AG
    Inventors: David Weninger Barnes, Scott Louis Cohen, Dean Franklin Rigel
  • SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP INHIBITORS
    Publication number: 20170015688
    Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides pharmaceutical composition of the compounds of the invention and a combination of pharmacologically active agents and a compound of the invention.
    Type: Application
    Filed: September 30, 2016
    Publication date: January 19, 2017
    Applicant: NOVARTIS AG
    Inventors: David Weninger BARNES, Scott Louis COHEN, Dean Franklin RIGEL
  • Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors
    Patent number: 9480693
    Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides pharmaceutical composition of the compounds of the invention and a combination of pharmacologically active agents and a compound of the invention.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: November 1, 2016
    Assignee: NOVARTIS AG
    Inventors: David Weninger Barnes, Scott Louis Cohen, Dean Franklin Rigel
  • SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP INHIBITORS
    Publication number: 20150374726
    Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides pharmaceutical composition of the compounds of the invention and a combination of pharmacologically active agents and a compound of the invention.
    Type: Application
    Filed: September 10, 2015
    Publication date: December 31, 2015
    Applicant: NOVARTIS AG
    Inventors: David Weninger BARNES, Scott Louis COHEN, Dean Franklin RIGEL
  • Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors
    Patent number: 9163040
    Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides pharmaceutical composition of the compounds of the invention and a combination of pharmacologically active agents and a compound of the invention.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: October 20, 2015
    Assignee: NOVARTIS AG
    Inventors: David Weninger Barnes, Scott Louis Cohen, Dean Franklin Rigel
  • Substituted bisphenyl butanoic acid derivatives as NEP inhibitors with improved in vivo efficacy
    Patent number: 9102635
    Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein X is defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides pharmaceutical composition of the compounds of the invention and a combination of pharmacologically active agents and a compound of the invention.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: August 11, 2015
    Assignee: NOVARTIS AG
    Inventors: David Weninger Barnes, Dean Franklin Rigel
  • SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP INHIBITORS
    Publication number: 20140228323
    Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides pharmaceutical composition of the compounds of the invention and a combination of pharmacologically active agents and a compound of the invention.
    Type: Application
    Filed: February 12, 2014
    Publication date: August 14, 2014
    Applicant: NOVARTIS AG
    Inventors: David Weninger BARNES, Scott Louis COHEN, Dean Franklin Rigel
  • Substituted bisphenyl butanoic acid derivatives as NEP inhibitors with improved in vivo Efficacy
    Publication number: 20140228415
    Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein X is defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides pharmaceutical composition of the compounds of the invention and a combination of pharmacologically active agents and a compound of the invention.
    Type: Application
    Filed: February 12, 2014
    Publication date: August 14, 2014
    Applicant: NOVARTIS AG
    Inventors: David Weninger BARNES, Dean Franklin RIGEL
  • Indoloquinazolinones
    Patent number: 6964960
    Abstract: The invention provides compounds of formula (I) wherein R is as defined in the description, and the preparation thereof. The compounds of formula (I) are useful as pharmaceuticals, for use in the treatment of any state associated with high levels of activeted PARP.
    Type: Grant
    Filed: July 16, 2001
    Date of Patent: November 15, 2005
    Assignee: Novartis AG
    Inventors: Kaspar Zimmermann, Robert Portmann, Dean Franklin Rigel
  • Indoloquinazolinones
    Publication number: 20030199502
    Abstract: The invention provides compounds of formula (I) wherein R is as defined in the description, and the preparation thereof. The compounds of formula (I) are useful as pharmaceuticals, for use in the treatment of any state associated with high levels of activeted PARP.
    Type: Application
    Filed: May 16, 2003
    Publication date: October 23, 2003
    Inventors: Kaspar Zimmermann, Robert Portmann, Dean Franklin Rigel